Abstract 2854
Background
Uveal melanoma (UM) is the most common intraocular malignancy. The disease is clinically and genetically distinct from cutaneous melanoma and shows a high rate of metastatic spread. As randomized clinical trials with immune checkpoint inhibitors (ICI) have not been performed in metastatic UM patients, we analysed the real-world outcomes in a nationwide population-based study.
Methods
Clinical data on patients with UM were extracted from the Danish Metastatic Melanoma database, a nationwide database containing unselected records of all Danish patients with metastatic melanoma. Diagnosis of primary UM was confirmed via the Copenhagen Epidemiological Uveal Melanoma Study database. Survival before (2011-2013, pre-ICI; n = 32) and after (2014-2018, post-ICI; n = 94) the approval of first-line treatment with ICI was analysed.
Results
Treatment and survival data were available from 126 metastatic UM patients. First-line treatment consisted of temozolomide in 28, ipilimumab in 24, pembrolizumab in 43 and the combination ipilimumab/nivolumab in 19 patients. Twelve patients did not receive any systemic treatment. No complete responses were observed. A partial response was observed in 7.0% of patients treated with pembrolizumab and in 21.1% treated with ipilimumab plus nivolumab. Median progression-free survival was 2.5 months for patients treated in the pre-ICI era compared to 3.7 months in the post-ICI era (HR 0.37; 95 CI 0.24-0.59; p < 0.01). The estimated 1-year overall survival rate increased from 25.0% to 41.9% and the median overall survival improved from 7.8 months to 10.0 months, respectively (HR 0.52; 95 CI 0.34-0.80; p < 0.01).
Conclusions
The introduction of ICI as first-line treatment appears to have significantly improved the real-world survival of patients with metastatic UM, despite relatively low response rates. With the lack of therapies proven effective in randomized trials, these data support the current treatment with ICI in patients with metastatic UM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Danish Melanoma Oncology Group.
Funding
The Danish Metastatic Melanoma database is supported by BMS, Roche, MSD and Novartis. K.F. Bol has received funding from the European Union (Marie Sklodowska-Curie grant).
Disclosure
K.F. Bol: Travel / Accommodation / Expenses: Roche. E. Ellebaek: Honoraria (self): BMS; Honoraria (self): Roche; Honoraria (self): Kyowa Kirin. M. Donia: Honoraria (self): BMS; Honoraria (self): Sanofi-Genzyme; Honoraria (self): MSD; Honoraria (self): AstraZeneca; Honoraria (self): Roche; Honoraria (self): Novartis. H. Schmidt: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): MSD; Honoraria (self), Advisory / Consultancy: Incyte; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Novartis. L. Bastholt: Advisory / Consultancy: MSD; Advisory / Consultancy: Incyte; Advisory / Consultancy: BMS; Advisory / Consultancy: Roche; Advisory / Consultancy: Eisai; Advisory / Consultancy: Novartis; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Bayer; Advisory / Consultancy: Amgen; Advisory / Consultancy: Swedish Orphan. I. Svane: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Roche; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Novartis; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy: Celgene; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Incyte; Honoraria (self), Advisory / Consultancy: TILT Bio; Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): BMS; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy, Shareholder / Stockholder / Stock options: IO Biotech. All other authors have declared no conflicts of interest.
Resources from the same session
5517 - Molecular fingerprinting in breast cancer (BC) screening using Quantum Optics (QO) technology combined with an artificial intelligence (AI) approach applying the concept of “molecular profiles at n variables (MPnV)”: a prospective pilot study.
Presenter: Jean-Marc Nabholtz
Session: Poster Display session 3
Resources:
Abstract
2152 - Inferring the correlation between incidence rates of melanoma and the average tumor-specific epitope binding ability of HLA class I molecules in different populations
Presenter: Istvan Miklos
Session: Poster Display session 3
Resources:
Abstract
4382 - Thermal Liquid Biopsy as a Valuable Tool in Lung Cancer Screening Programs
Presenter: Alberto Rodrigo
Session: Poster Display session 3
Resources:
Abstract
2465 - Towards a screening test for cancer by circulating DNA analysis
Presenter: Rita Tanos
Session: Poster Display session 3
Resources:
Abstract
3788 - Evaluation of a successful launch of the MammaPrint and BluePrint NGS kit
Presenter: Leonie Delahaye
Session: Poster Display session 3
Resources:
Abstract
3863 - Analysis of prognostic factors on overall survival in elderly women treated for early breast cancer using data mining and machine learning
Presenter: Pierre Heudel
Session: Poster Display session 3
Resources:
Abstract
1993 - Circulating tumor cell detection in epithelial ovarian cancer using dual-component antibodies targeting EpCAM and FRα
Presenter: Na Li
Session: Poster Display session 3
Resources:
Abstract
4281 - CEUS of the breast: Is it feasible in improved performance of BI-RADS evaluation of critical breast lesions?——A multi-center prospective study in China
Presenter: Jun Luo
Session: Poster Display session 3
Resources:
Abstract
2268 - Classification of abnormal findings on ring-type dedicated breast PET for detecting breast cancer
Presenter: Shinsuke Sasada
Session: Poster Display session 3
Resources:
Abstract
4035 - Prediction of benign and malignant breast masses using digital mammograms texture features
Presenter: Cui Yanhua
Session: Poster Display session 3
Resources:
Abstract